|Articles|December 1, 2015
- Applied Clinical Trials-12-01-2015
- Volume 24
- Issue 12
Applied Clinical Trials Digital Edition - December 2015/January 2016
Regulatory: Assessing Study Drop in CEE Swiss Syncs Up Regulations Sites: Regional Risks in Eastern Europe Also in this issue: Orphan Drug Hurdles in Europe Patient Engagement: Illness-Level Impact Clinical Trial Technology in 2025
Advertisement
Articles in this issue
almost 10 years ago
Orphans of the Stormalmost 10 years ago
Technology-Driven R&D to be Prime Topic at DIA’s EuroMeetingalmost 10 years ago
How Will Technology Drive Global Clinical Trial Change by 2025?almost 10 years ago
New EU Trials Law: Headway, Concernsalmost 10 years ago
Switzerland Guides Innovation in Clinical Trial Regulationsalmost 10 years ago
Decline of Trials in CEE: Fluctuation or Trend?almost 10 years ago
Site Challenges in Eastern Europealmost 10 years ago
Rethinking Patient Engagement: Mild vs. Severe Illnessalmost 10 years ago
Patients, PDUFA, Pandemics to Shape R&D in 2016almost 10 years ago
Applied Clinical Trials, December 2015/January 2016 Issue (PDF)Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
2
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
3
FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains
4
Designing Feasible Protocols with Real-World Data
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
